MedTrace Logo

Combination Targeted Radiotherapy in Neuroendocrine Tumors

NCT01099228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-07-21

No results posted yet for this study

Summary

The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.

Conditions

Interventions

OTHER

131-I MIBG and 111-In pentetreotide

Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)

OTHER

131-I MIBG and In-111 DOTATATE

131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • David Bushnell

    lead OTHER

Principal Investigators

  • David Bushnell, M.D. · University of Iowa; Veteran Affairs

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-04-30
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01099228 on ClinicalTrials.gov